

SUPPLEMENTARY

eTable 1 - Baseline characteristics of the ParkWest study PD subjects that were included or excluded/not available for this study

| | All PD ^a | PD – included ^a | PD – not available/ excluded ^a | <i>p</i> -value |
|----------------------------------|---------------------|----------------------------|--|--------------------|
| N | 190 | 117 | 73 | |
| Age, years | 68.0 ± 9.2 | 67.2 ± 9.5 | 69.2 ± 8.8 | 0.159 ^b |
| Sex Male, n (%) | 116 (61%) | 76 (65%) | 40 (55%) | 0.172 ^c |
| Education, years | 11.2 ± 3.3 | 11.2 ± 3.1 | 11.1 ± 3.6 | 0.832 ^b |
| MMSE, total score | 27.7 ± 2.4 | 27.7 ± 2.4 | 27.8 ± 2.4 | 0.843 ^b |
| UPDRS III, total score | 22.5 ± 11.3 | 22.4 ± 10.6 | 25.2 ± 12.1 | 0.088 ^b |
| Hoehn and Yahr stage, ≥ 3, n (%) | 20 (10.5) | 10 (8.5) | 10 (13.7) | 0.332 ^c |
| Stage 1, n (%) | 31 (16.3) | 21 (17.9) | 10 (13.7) | - |
| Stage 1.5, n (%) | 45 (23.7) | 28 (23.9) | 17 (23.3) | - |
| Stage 2, n (%) | 64 (33.7) | 39 (33.3) | 25 (34.2) | - |
| Stage 2.5, n (%) | 30 (15.8) | 19 (16.2) | 11 (15.1) | - |
| Stage 3, n (%) | 17 (8.9) | 9 (7.7) | 8 (11.0) | - |
| Stage 4, n (%) | 3 (1.6) | 1 (0.9) | 2 (2.7) | - |
| Stage 5, n (%) | 0 | 0 | 0 | - |

^a The ParkWest study includes 190 participants with a confirmed clinical diagnosis of PD according to the UK brain bank criteria¹³ at their latest or final clinical visit. 120 participants consented to lumbar puncture but samples from 3 participants were excluded for technical reasons (see Materials and Methods), leaving 117 participants eligible for this study.

^b Independent t-test and ^c Chi-square test were used for group comparisons between those PD cases included and those not available/excluded

Values are presented as mean ± SD.

Abbreviations: UPDRS III: Unified Parkinson's Disease Rating Scale part III; MMSE: Minimal-Mental State Examinations.